Compare Albemarle Corp. (ALB) vs Medtronic PLC (MDT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albemarle Corp. vs Medtronic PLC — how do they compare? Albemarle Corp. trades at $127.46 (market cap $15.22B), while Medtronic PLC trades at $82.39 (market cap $107.31B). The key difference: Medtronic PLC is far larger — about 7.1× Albemarle Corp.'s market cap, and Medtronic PLC pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| ALB | MDT | |
|---|---|---|
Market Cap | $15.22B | $107.31B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $105.35 |
52-Week Low | $67.30 | $73.75 |
Enterprise Value | $18.24B | $126.05B |
Dividend Yield | 1.26% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
Medtronic (MDT) trades at $83.83, up 0.77% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company shows improving fundamentals with 2025 revenue of $33.54B and net income of $4.66B, supported by a 13.2% net margin. Recent acquisition of Scientia Vascular enhances its neurovascular portfolio, while analyst consensus remains strongly positive with a $98.77 price target.
MDT presents a compelling investment case with steady growth, a 3.5% dividend yield, and undervaluation relative to analyst targets. Key risks include rising debt levels and margin pressures from tariffs. The stock's current position near support levels offers a potential entry point for long-term investors seeking healthcare sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
